Updates are available Correction dated 2024-04-05
Click to view Correction: https://doi.org/10.1038/s41591-024-02966-z
-
Authors
Irwin, Katherine E. http://orcid.org/0000-0001-8941-4557
Jasin, Pei
Braunstein, Kerstin E.
Sinha, Irika R. http://orcid.org/0000-0001-6440-7019
Garret, Mark A. http://orcid.org/0000-0002-3350-338X
Bowden, Kyra D.
Chang, Koping http://orcid.org/0000-0001-7873-3640
Troncoso, Juan C.
Moghekar, Abhay http://orcid.org/0000-0001-9464-1551
Oh, Esther S.
Raitcheva, Denitza
Bartlett, Dan
Miller, Timothy
Berry, James D. http://orcid.org/0000-0003-0898-6081
Traynor, Bryan J. http://orcid.org/0000-0003-0527-2446
Ling, Jonathan P. http://orcid.org/0000-0003-1927-9729
Wong, Philip C. http://orcid.org/0000-0001-8162-3274
-
Funding
Funding for this research was provided by:
Johns Hopkins | SOM, JHU | Robert Packard Center for ALS Research, Johns Hopkins University
Target ALS
Amyotrophic Lateral Sclerosis Association
U.S. Department of Health & Human Services | National Institutes of Health (R01NS095969)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (1ZIAAG000933)
Alzheimer’s Association
- License Information
-
More Information
Article History
Received: 24 January 2023
Accepted: 21 December 2023
First Online: 26 January 2024
Change Date: 5 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-02966-z
Competing interests
: The authors declare the following competing interests. J.P.L. and P.C.W. are inventors on a provisional patent application submitted by Johns Hopkins University that covers the usage of TDP-43-associated cryptic exon-derived neoepitopes as biomarkers. B.J.T. holds patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of <i>C9orf72</i>. D.B. is an employee and shareholder of Biogen. At the time of the study, D.R. was an employee and shareholder of Biogen.
